Horizon Therapeutics: Combining generic pain meds for greater drug safety
Palo Alto, Calif.-based Horizon Therapeutics, a biotech that aims to combine existing generic drugs to fight pain, raised $30 million in a third funding round. The company’s lead drug candidate, known only as HZT-501, is a “proprietary” combination of the generic drugs ibuprofen and famotidine,… Continue Reading
Horizon Therapeutics, stomach ulcer treatment co., raises $15M
Horizon Therapeutics, a Palo Alto company close to bringing its stomach ulcer drug into the third and last set of clinical trials, said it has raised $15 million in a second round of funding.
Its lead product is HZT-501, a “GI-friendly” prescription NSAID.
Scale Venture Partners, formerly… Continue Reading